rEV 131

Drug Profile

rEV 131

Alternative Names: EV-131; rEV-131

Latest Information Update: 09 May 2007

Price : $50

At a glance

  • Originator Evolutec
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Recombinant proteins
  • Mechanism of Action Histamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Allergic conjunctivitis; Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease; Postoperative inflammation

Most Recent Events

  • 04 Dec 2006 A phase IIb trial of rEV 131 in Allergic rhinitis did not meet its primary endpoint
  • 22 Jun 2006 Phase-II clinical trials in Postoperative inflammation in USA (Ophthalmic)
  • 16 Jun 2006 Phase-II clinical trials in Allergic rhinitis in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top